MapLight Therapeutics, Inc. (MPLT)
7.25
+0.18
(+2.55%)
USD |
NASDAQ |
Nov 13, 16:00
7.25
0.00 (0.00%)
After-Hours: 19:59
MapLight Therapeutics Enterprise Value : 26.68M for Nov. 13, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2026 | 26.68M |
| November 12, 2026 | 18.50M |
| November 11, 2026 | 37.13M |
| November 10, 2026 | 35.31M |
| November 09, 2026 | 28.04M |
| November 06, 2026 | 12.14M |
| November 05, 2026 | -20.12M |
| November 04, 2026 | 2.144M |
| November 03, 2026 | 6.687M |
| November 02, 2026 | 5.324M |
| October 30, 2026 | 41.67M |
| October 29, 2026 | 48.03M |
| October 28, 2026 | 59.85M |
| October 27, 2026 | 68.48M |
| October 26, 2026 | 45.31M |
| October 23, 2026 | 59.39M |
| October 22, 2026 | 72.12M |
| October 21, 2026 | 68.03M |
| October 20, 2026 | 71.66M |
| October 19, 2026 | 60.76M |
| October 16, 2026 | 47.13M |
| October 15, 2026 | 61.67M |
| October 14, 2026 | 52.12M |
| October 13, 2026 | 55.08M |
| October 12, 2026 | 88.02M |
| Date | Value |
|---|---|
| October 09, 2026 | 98.47M |
| October 08, 2026 | 113.01M |
| October 07, 2026 | 122.55M |
| October 06, 2026 | 137.55M |
| October 05, 2026 | 118.69M |
| October 02, 2026 | 143.45M |
| October 01, 2026 | 134.82M |
| September 30, 2026 | 160.26M |
| September 29, 2026 | 158.45M |
| September 28, 2026 | 172.08M |
| September 25, 2026 | 172.53M |
| September 24, 2026 | 186.16M |
| September 23, 2026 | 186.62M |
| September 22, 2026 | 190.71M |
| September 21, 2026 | 192.52M |
| September 18, 2026 | 193.43M |
| September 17, 2026 | 211.61M |
| September 16, 2026 | 215.24M |
| September 15, 2026 | 246.14M |
| September 14, 2026 | 294.76M |
| September 11, 2026 | 287.94M |
| September 10, 2026 | 323.61M |
| September 09, 2026 | 320.20M |
| September 08, 2026 | 331.11M |
| September 04, 2026 | 322.93M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Oncolytics Biotech, Inc. | 46.90M |
| Sangamo Therapeutics, Inc. | 40.22M |
| Sarepta Therapeutics, Inc. | 1.897B |
| Anixa Biosciences, Inc. | 75.65M |
| Vicapsys Life Sciences, Inc. | 16.68M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -60.19M |
| Total Expenses (Quarterly) | 60.19M |
| EPS Diluted (Quarterly) | -1.325 |
| Earnings Yield | -70.65% |
| Normalized Earnings Yield | -70.65 |